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Summary We investigated the role of platelets in human melanoma cell (line 397) interaction with vascular endothelial cells (ECs) underflow
conditions. The ability of the tumour cells to adhere to the EC monolayer was significantly reduced by application of flow at a shear rate of
250 s-1. A 2.2-fold increase in tumour cell adhesion to ECs under flow was observed upon addition of thrombin receptor agonist peptide
(TRAP)-activated platelets but not resting platelets. A similar increase (2.5-fold) in tumour cell adhesion to ECs under flow was observed
when the tumour cells were incubated with resting platelets on thrombin-treated ECs. However, thrombin treatment of the ECs alone had no
effect on tumour cell adhesion in the absence of platelets. The enhancement of tumour cell adhesion to ECs by TRAP-activated platelets was
virtually abolished by blockade of the platelet glycoproteins P-selectin and GPIlb-lila by monoclonal antibodies. Blockade of P-selectin also
inhibited the direct adhesion ofTRAP-activated platelets to ECs, but did not affectthe interaction of the tumour cells with platelets immobilized
on subendothelial extracellular matrix (ECM). Blockade of GPIlb-llla inhibited both platelet-EC and platelet-tumor cell interactions. Our
results indicate that tumour cell adhesion to the endothelium under flow is enhanced by platelets under conditions that allow platelet adhesion
to ECs. Inhibition studies suggest that activated platelet adhesion to ECs is mediated by P-selectin and GPIlb-IIIA, and tumour cell adhesion
to EC-bound platelets - mainly by GPIlb-llla.
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Tumour cell adhesion to the vessel wall is one of the earliest
events initiating tumour metastasis. Numerous in vivo and in vitro
studies have demonstrated that platelets greatly potentiate tumour
metastasis by virtue of their ability to interact with both tumour
cells and vessel wall components (for review see Honn et al, 1992
and Nierodzik et al, 1995). Intact vascular endothelium covering
the vessel wall is normally non-thrombogenic. However, in vitro
studies have shown that platelets can adhere to endothelial cells
(ECs) stimulated with certain agonists, e.g. lipopolysaccharides or
interleukin I f (Diquelou et al, 1995). It was also reported that
thrombin treatment of ECs alone (Kaplan et al, 1989) or of ECs
and platelets simultaneously (Li et al, 1996) leads to increased
platelet adherence to the endothelium.
The thrombin receptor present on platelets and ECs is a G-
protein-coupled seven transmembrane domain protein. The extra-
cellular amino terminus of the receptor contains a thrombin
cleavage site located between Arg-41 and Ser-42. Cleavage at this
site exposes a new amino terminus that acts as a tethered ligand
binding to another transmembrane domain to cause receptor acti-
vation (Coughlin, 1993). Synthetic peptides containing the first N-
terminal 5 amino acids ofthe tethered ligand, SFLLR, are capable
of activating the thrombin receptor without thrombin cleavage.
These peptides, known as thrombin receptor agonist peptides
(TRAPs), are assumed to mimic the effect ofthrombin by inducing
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a conformational change in the receptor required to activate the G-
proteins that are coupled to its cytoplasmic domain (Coughlin,
1993). Thrombin is a potent platelet agonist causingphosphoinosi-
tide hydrolysis, increase in cytosolic Ca2+, suppression of cAMP
synthesis and protein phosphorylation on serine, threonine and
tyrosine residues (Brass and Hoxie, 1993). The intracellular events
triggered by thrombin receptor activation on ECs are activation of
phospholipases A2, C and D and elevation ofcytosolic Ca2+ (Brass
and Molino, 1997). In addition, thrombin stimulates secretion of
platelet-activating factor, platelet-derived growth factor, von
Willebrand factor (Brass and Molino, 1997), as well as secretion
and surface expression ofP-selectin (Kameda et al, 1997).
Normal endothelium prevents activation of the coagulation
cascade and platelet stimulation by a variety of mechanisms
(Moncada et al, 1987). However, many tumour cells express tissue
factor (Callander, 1992) or cancer procoagulant (Donati et al,
1986), and are thus capable of activating the coagulation system
leading to increased thrombin generation and, therefore, increased
thrombogenicity of the endothelium. In the present study, we
addressed the potential contribution of increased thrombogenicity
to tumour metastasis. We have recently shown that tumour cell
adhesion to the subendothelial extracellular matrix (ECM) occur-
ring under static conditions is almost completely abolished upon
introduction of physiological flow conditions and that ECM-
bound platelets can partially restore tumour cell adhesion to the
ECM under flow (Dardik et al, 1997). In the present work, we
extended our studies and investigated the role of platelet and/or
EC activation via the thrombin receptor in platelet-mediated
adhesion oftumour cells to intact vascularendothelium under flow
conditions resembling those existing in the arteries (Slack et al,
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1993). We find that tumour cell adhesion to ECs is significantly
enhanced by platelets when the platelets are activated by TRAPs,
or when the ECs are pretreated with thrombin. This complex inter-
action is dependent on both P-selectin and GPIIb-IIIa.
MATERIALS AND METHODS
Antibodies
MAbs against GPIIb-IIIa (CD41a; clone P2: inhibits fibrinogen
binding and platelet aggregation) and GPIb-IX complex (CD42b;
clone SZ2: inhibits binding of von Willebrand factor and
ristocetin-induced platelet agglutination) were purchased from
Immunotech (Marseille, France). MAb against P-selectin (CD62P;
clone AK-6) was purchased from Serotec (Oxford, UK). Non-
immune mouse IgG was obtained from Sigma Chemicals (Israel).
Cell cultures
Bovine aortic endothelial cells were obtained from the aortic arch
as described previously (Savion et al, 1984). Cells were cultured in
Dulbecco's Modified Eagle Medium (DMEM) supplemented with
10% calf serum, 2 mm glutamine, penicillin (100 u ml-'), strepto-
mycin (0.1 mg ml-') and nystatin (12.5 u ml-'). The cells were
passaged once a week and human recombinant bFGF (3 ng ml-')
was added every other day until a confluent monolayer was
obtained. ECs were used from passage 5 up to passage 15. Human
melanoma cell line 397 was kindly provided by Dr SA Rosenberg
(NCI, Bethesda, MD, USA) and grown as described previously
(Dardik et al, 1997).
Platelet preparation
Platelet-rich plasma (PRP) was prepared by centrifugation of
citrated whole blood for 15 min at 120g. Radiolabelling was
performed according to the method described by Harker and
Finch, 1969. A 3-ml sample ofPRP was incubated with 0.3 mCi of
[5'Cr]-disodium chromate (DuPont, NEN Products, UK) for 20
min. Radiolabelled platelets were washed from free chromium by
addition of 12 ml of Tyrode's buffer (pH 6.5) and centrifugation
for 10 min at 800g. Platelets were then resuspended in autologous
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Table 1 Adhesion of 397 melanoma cells to ECs under static and flow
conditions
Adherent cells per well (x 10-3)
Static conditions Flow conditions
(250 s-1)
Non-treated EC 27.3 ± 4.1 1.7 ± 0.3
Thrombin-treated EC 30.2 ± 2.5 2.0 ± 0.4
Melanoma cell line 397 cells were incubated with either non-treated ECs or
thrombin-treated ECs under static or flow conditions for 15 min at 37°C.
Adhesion was determined as described in Materials and methods.
citrated plasma to a final volume of 3 ml (sp. act. 50 000-
80 000 c.p.m per 107 platelets). Platelet activation in PRP was
performed by addition of 14-mer TRAP (Sigma Chemicals, Israel)
at a final concentration of4 ,UM for 5 min. No platelet aggregation
occurred under these conditions. Platelet preparation, radio-
labelling and activation were performed at 220C.
Preparation of ECM plates coated with adherent
platelets
For ECM preparation, bovine endothelial cells grown to conflu-
ence were dissolved in 0.5% Triton X-100 in phosphate-buffered
saline (PBS) for 30 min at 22°C. Residual nuclei and cytoskeleton
were removed by brief incubation with 0.1 M ammonium
hydroxide, followed by extensive washings with PBS. Platelet-
coated ECM plates were prepared by addition of0.2 ml ofPRP for
30 min at 22°C, followed by washing with PBS. To test the effects
of anti-platelet antibodies, ECM-bound platelets were incubated
with the MAb of interest (20 ,ug ml-') for 30 min at 22°C and
washed with PBS before the addition oftumour cells.
Cell adhesion experiments
Melanoma cell line 397 cells were labelled with 1 gCi ml-'
[3H]thymidine for 16 h in culture medium (Savion et al, 1984).
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Figure 1 The effect of resting and activated platelets on 397 cell adhesion to ECs. Melanoma cell line 397 cells (1 x 105) were incubated with confluent EC
monolayers for 15 min in the presence of resting or TRAP-activated platelets in PRP (1 x 107) under static (A) or flow at 250 s-1 (B) conditions. The amount of
adherent cells was determined as described in Materials and methods. Results are expressed as means ± s.d. of three experiments performed in
quadruplicates. *Significantly different (P < 0.05) from the value obtained in the absence of platelets under flow
British Journal of Cancer (1998) 77(12), 2069-2075
+ _ - + _ +
_ + + _ _ + +
0 CancerResearch Campaign 1998Thrombin andplatelets promote tumourmetastasis 2071
A~~~~~~~ 40 * 4
3 -
3 ,i.._. .i
10
EC+T1Wv - I + pPF -P +
Figure 2 The effect of EC treatment with thrombin and platelet addition on 397 cell adhesion to EC. Melanoma cell line 397 cells (1 x 105) were incubated with
either non-treated or thrombin-treated EC monolayers in the absence or presence of platelets (1 x 107) under either static (A) or flow at 250s-1 (B) conditions for
15 min. The amount of adherent cells was determined as described in Materials and methods. Results are expressed as means+ s.d. of three experiments
performed in quadruplicates. *Significantly different (P < 0.01) from the value obtained on non-treated endothelium in the absence of platelets
A concentration of 1 x 106 cells ml-' to be further diluted as required.
In time course experiments 0.25-ml aliquots containing 1 x 105
cells in FCS-containing medium were incubated with confluent
EC monolayers in four-well tissue culture plates for varying
periods at 37°C. In all other experiments the incubation period was
15 min. In experiments testing the effect ofplatelets, radiolabelled
397 cells (Ix l05; 70000-1O0 000 c.p.m) were mixed with lx 107
either resting or TRAP-activated platelets in PRP and the sample
volume was adjusted to 0.25 ml. In some experiments the EC
monolayers were preincubated with 1 u ml-' of human oc-thrombin
(kindly provided by Dr J Fenton II, New York Department of
Health, Albany, NY, USA) for 30 min at 37°C and washed twice
with PBS before the addition of the 397 cells mixed with resting
platelets. Flow at shear rate of 250 s-' was created using a cone and
plate device especially designed to fit the four-well plates (Varon
et al, 1997). Under these conditions the EC monolayer always
remained intact as determined by examination of the plates by
phase and scanning electron microscopy. After incubation, the
wells were gently washed twice with PBS, bound cells were
collected by solubilization in a 2% sodium dodecyl sulphate (SDS)
solution and the samples were counted in a P-scintillation counter.
For scanning electron microscope (SEM) analysis, the samples
- _ were fixed with 2.5% glutaraldehyde in PBS and processed using a
standard technique (Lavee et al, 1989).
Platelet adhesion experiments
l XS; +/i _||;l Aliquots of 0. I ml containing I x 107 radiolabelled platelets in
autologous plasma (either resting or TRAP-activated as described
above) diluted with 0.15 ml of RPMI- 1640 medium supplemented
with 10% FCS were incubated with either untreated or thrombin-
treated EC-coated wells under flow conditions (250 s ')for 15 min
Figure 3 Scanning electron microscope analysis of 397 melanoma cells
bound to thrombin-treated ECs in the absence (A) or in the presence (B) of at 370C. The wells were gently washed with PBS and bound
platelets underflow conditions. Note the complete absence of 397 cells in A platelets were collected by solubilization in a 2% SDS solution and
and the formation oftumour-platelet aggregates in B. counted in a y-counter.
Labelled cells were harvested by incubation with calcium and Statistical analysis
magnesium-free PBS containing 5 mm EDTA for 10 min at 370C, Statistical analysis of differences between means was performed
washed with RPMI-1640 medium supplemented with 10% fetal using the unpaired two-tailed Student's t-test at a confidence
calf serum (FCS) and resuspended in the same medium at a interval of95%.
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Figure 4 Effect of MAbs on platelet-mediated tumour cell adhesion to ECs. (A) Melanoma cell line 397 cells (1 x 105) were incubated for 15 min under flow
conditions at 250 s-1 with non-treated EC monolayers in the presence of TRAP-activated platelets (1 x 107) that, after TRAP activation and before mixing with
the tumour cells, were preincubated with the indicated MAbs (20 ,ug ml-') for 15 min. Alternatively, 397 cells were incubated under the same conditions with
thrombin-treated ECs in the presence of platelets and the indicated MAbs (20 pg ml-'). (B) Melanoma cell line 397 cells were incubated under flow conditions
with ECM-bound platelets preincubated with the indicated MAbs (20 ,g ml-'). The amount of adherent cells was determined as described in Materials and
methods. Results are expressed as means + s.d. of three experiments performed in quadruplicates. *P < 0.05 and **P < 0.01 significantly different compared
with the value observed in the absence of antibodies
RESULTS
Effect of thrombin treatment and flow on tumour cell
adhesion to ECs
Under static conditions, 397 melanoma cells bound to the EC
monolayer in a time-dependent and saturable manner, with
submaximal binding after 15 min of incubation (data not shown).
Therefore, in further experiments testing the effects of flow,
platelets and thrombin the incubation period was 15 min.
Pretreatment of the ECs with thrombin did not significantly affect
tumour cell adhesion (Table 1). The application of flow at 250 s-'
has greatly decreased the extent ofmelanoma cell adhesion to both
non-treated and thrombin-treated ECs (Table 1). The extent of
adhesion to both non-treated and thrombin-treated ECs under flow
remained very low at longer incubation periods up to 30 min (data
not shown).
Tumour cell adhesion to ECs: effect of thrombin
treatment of EC and resting or activated platelets
Melanoma cell adhesion to non-treated endothelium was not
affected by the presence of resting platelets independently of the
flow conditions. Adhesion of the tumour cells to non-treated ECs
was significantly increased by the addition of TRAP-activated
platelets under flow, but not under static conditions (Figure 1). The
extent of tumour cell adhesion to ECs in the absence of platelets
was not affected by pretreatment of the 397 cells with TRAP
(Figure 1).
Adhesion of 397 cells to thrombin-treated endothelium was
significantly increased by the addition of platelets under flow, but
not under static conditions (Figure 2). Melanoma cell line 397 cell
adhesion to thrombin-treated endothelium under static conditions
was not affected by platelets at either shorter or longer incubation
periods varying from 5 to 60 min (data not shown).
Examination using SEM revealed that under flow conditions
tumour cells were associated with platelet aggregates (Figure 3).
Treatment of the ECs with TRAP instead of thrombin did not
affect tumour cell adhesion in the presence of platelets under flow
(data not shown).
Taken together, these results suggest a role for platelets in the
process of tumour cell adhesion to the vessel wall. Furthermore,
thrombin treatment of the endothelium or platelet activation by
TRAP is required in order to achieve enhancement of tumour cell
adhesion under flow.
The role of platelet glycoproteins in platelet-mediated
adhesion of tumour cells to the EC monolayer under
flow
The enhancement of 397 melanoma cell adhesion to non-treated
ECs by TRAP-activated platelets was almost completely abolished
by preincubation of the activated platelets with MAbs against
GPIIb-IIIa or P-selectin before mixing with the tumour cells.
Preincubation with anti-GPIb-IX complex antibody has only
slightly reduced platelet-mediated 397 cell adhesion under flow.
The enhancing effect of resting platelets on tumour cell adhesion
to thrombin-treated endothelium was also greatly diminished by
blockade of P-selectin or GPIIb-IIIa, but remained virtually
unaffected by blockade ofthe GPIb-IX complex (Figure 4A).
We have recently shown that the GPIIb-IIIa integrin plays
a major role in tumour cell-platelet interaction on the ECM
(Dardik et al, 1997). To clarify the role of P-selectin in this inter-
action, we tested the effects of anti-GPIIb-IIIa and anti-P-selectin
antibodies on the adhesion of 397 melanoma cells to platelets
immobilized on the ECM. As shown in Figure 4B, blockade of
P-selectin had no effect on melanoma cell adhesion to ECM-
bound platelets, whereas blockade of GPIIb-IIIa resulted in
marked inhibition.
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Figure 5 Effect of ECs and platelet activation on platelet adhesion to ECs.
Resting or TRAP-activated 5'Cr-labelled platelets were incubated with either
non-treated or thrombin-treated ECs under flow condition at 250s-1 for
15 min. The amount of adherent platelets was determined as described in
Materials and methods. Results are expressed as means ± s.d. of three
experiments performed in quadruplicates. *Significantly different (P < 0.05)
from the value obtained with TRAP activated platelets in the absence of
antibodies
Platelet adhesion to ECs is enhanced by thrombin
treatment of ECs or by platelet activation: role of
P-selectin and GPlIb-lila
To further identify the receptors involved in the specific
tumour-platelet and platelet-EC interactions, we have studied the
interaction ofplatelets with ECs. 5"Cr-labelled platelets were incu-
bated with either non-treated or thrombin-treated EC monolayer
under the same flow conditions as those used in experiments with
the melanoma cells (250 s-'). Alternatively, the platelets were acti-
vated by TRAP before the incubation with non-treated endothe-
lium. Platelet adhesion to ECs was significantly increased by
either pretreatment of the EC monolayer with thrombin or by
platelet activation with TRAP (fold enhancement: 2.8 and 3.3
respectively). The enhancing effect ofTRAP activation was signif-
icantly reduced when either P-selectin or GPIIb-IIIa were blocked
by monoclonal antibodies after activation (Figure 5).
Taken together, these results suggest that the interaction
between activated platelets and ECs involves both P-selectin and
GPIIb-IIIa, whereas the interaction of melanoma cells with
platelets is mediated mainly by GPIIb-IIIa.
DISCUSSION
We have recently demonstrated that tumour cell adhesion to the
subendothelial ECM under flow conditions is greatly enhanced by
ECM-adherent platelets (Dardik et al, 1997). In the present work,
we have extended our studies to examine the role ofplatelets in the
interaction of tumour cells with vascular ECs under flow condi-
tions, with a special emphasis on the effect of platelet activation
via the thrombin receptor by either TRAP or by EC-bound
thrombin.
Tumour cell metastasis is initiated by binding of the malignant
cells to the EC monolayer lining the vessel wall, followed by
retraction of the ECs leading to exposure of the subendothelium
(Honn et al, 1992), which is a highly adhesive substrate. It is a
widely accepted concept that subendothelial ECM is a better
substrate for adhesion of tumour cells than the intact endothelial
monolayer (Nicolson and Custead, 1985). Similarly to others, we
have also observed preferential adherence of tumour cells to the
ECM compared with that found with the EC monolayer (unpub-
lished data). However, this difference in the ability to support
tumour cell adhesion could be seen under static conditions, but not
under conditions of physiological blood flow when tumour cell
adhesion to both substrates was low compared with that observed
under static conditions (Dardik et al, 1997; Table 1). Poly-
morphonuclear leucocyte (Lawrence et al, 1987) and neutrophil
(Kuijper et al, 1996) adhesion to the endothelium was also shown
to be greatly impaired by flow. We find that adhesion of tumour
cells to both the ECM (Dardik et al, 1997) and the EC monolayer
under flow is enhanced by the presence of platelets (Figures 1 and
2). In contrast to the subendothelial ECM, which is a highly throm-
bogenic surface inducing rapid platelet adhesion and activation,
the intact endothelium is non-thrombogenic. Thus, tumour cell
adhesion to the ECM is enhanced by platelets, regardless of their
activation state (Dardik et al, 1997), as platelets become activated
upon adhesion to the ECM. In the case of intact endothelium,
however, the enhancing effect of platelets was found to be depen-
dent on either platelet activation by TRAP or on preincubation
of the ECs with thrombin (Figures 1 and 2), both treatments
increasing the thrombogenicity of the endothelium, i.e. enhancing
platelet adhesion to ECs (Figure 5). A similar increase in platelet
adhesion to ECs after thrombin treatment of EC or thrombin-
induced platelet activation has been reported by others (Kaplan et
al, 1989; Li et al, 1996). The ability of thrombin-treated ECs to
support platelet adhesion was suggested to result from binding and
retention of active thrombin on the EC surface, capable of platelet
activation (Kaplan et al, 1989). The inability ofTRAP treatment of
the endothelium to enhance either platelet adherence to ECs or
tumour cell adherence in the presence of resting platelets (our
unpublished observations) is in agreement with this interpretation.
It must be noted that the system used by us is heterologous, i.e.
composed of bovine endothelium and human platelets and
melanoma cells. Unfortunately, in contrast to bovine cells, human
umbilical vein endothelial cells (HUVECs) were very sensitive to
degradation by the melanoma cells: incubation of the 397 cells
with HUVECs resulted in formation of large gaps, thus making
them unsuitable for adhesion experiments. However, the effect of
platelet activation by TRAP or ofthrombin treatment ofthe human
endothelium on platelet adhesion was the same as that observed
with bovine endothelium: either of the treatments induced
enhancement ofplatelet adhesion to ECs regardless ofthe origin of
the endothelium. As factors increasing thrombogenicity are the
same in both systems, and increased thrombogenicity leads to
increased tumour cell adhesion, we may assume that our findings
are physiologically relevant to the human situation.
Platelet activation is accompanied by release of granular contents
and expression of the alpha-granule glycoprotein P-selectin. Several
reports have shown that P-selectin mediates platelet interaction with
polymorphonuclear leucocytes under flow conditions (Diacovo et al,
1996; Kuijper et al, 1996). In vivo studies have demonstrated defec-
tive platelet rolling on activated endothelium (Frenette et al, 1995)
and prolongation ofbleeding time by40% (Subramaniam et al, 1996)
in P-selectin-deficient mice, indicating that P-selectin plays an
important role in haemostasis. Our results suggest that P-selectin is
also involved in platelet-mediated tumour cell adhesion to ECs under
flow conditions (Figure 4A). It seems that in our system, P-selectin
plays an important role mainly in the interaction ofactivated platelets
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with the ECs (Figure 5), but not in the interaction between adherent
platelets and tumour cells, which is not affected by P-selectin
blockade (Figure 4B). In contrast, the major platelet integrin GPIIb-
Illa is involved in both the adherence of activated platelets to the
endothelium (Figure 5) and the interaction of platelets with tumour
cells (Figure 4B). Activated platelets express GPIIb-IIIa in its active
conformation capable of binding adhesive glycoproteins such as
fibrinogen, von-Willebrand factor and thrombospondin, all of which
are present in the plasma and, in addition, are stored within the
resting platelet, secreted upon platelet activation and can bind to acti-
vated GPIIb-IIIa. These adhesive glycoproteins are also capable of
binding to the xc53-integrin, which is expressed by ECs as well as by
melanoma cells and is known to participate in platelet-tumour cell
interaction (Dardik et al, 1997; Felding-Habermann et al, 1996). One
or more of the adhesive ligands recognized by both GPIIb-IIIa
and ocx -,-integrins might, therefore, act as a bridge mediating
platelet-tumour cell and platelet-endothelial cell interactions. The
nature ofthe EC ligand forplatelet P-selectin, the additional mediator
ofplatelet adherence to the endothelium, is unknown. Possible candi-
dates might be fucosylated or sialylated saccharide moieties present
on the cell membrane glycoproteins (Furie and Furie, 1995). Studies
with knock-out mice have stressed the importance of endothelial
P-selectin, rather than that ofplatelet P-selectin, in platelet rolling on
activated endothelium (Frenette et al, 1995). In our system, the role
ofendothelial P-selectin cannot be investigated because ofthe lack of
recognition of bovine P-selectin by a MAb raised against human P-
selectin. However, using this MAb in the heterologous bovine/
human system enabled us to evaluate the role ofplatelet P-selectin in
the adherence of activated platelets to the endothelium, which was
found to be important. The discrepancy between our findings and
those reported by Frenette et al, 1995) with respect to the role of
platelet P-selectin in platelet-endothelium interaction might reflect
differences in the molecular interactions involved in platelet rolling
vs platelet adherence to the endothelium.
Previous studies performed under static conditions have shown
that thrombin stimulates tumour cell adhesion to platelets
(Nierodzik et al, 1992), as well as to ECs and to the subendothe-
lium (Klepfish et al, 1993). Thrombin is also known to greatly
enhance tumour metastasis in vivo (Nierodzik et al, 1992). A
recent report shows that several tumour cell lines express the
seven-transmembrane thrombin receptor (Nierodzik et al, 1997).
The 397 melanoma cells used by us in this study did not exhibit
increased adhesion to either the ECM or the EC monolayer upon
thrombin treatment in suspension (data not shown). Furthermore,
thrombin treatment of the endothelium by itself did not affect
melanoma cell adhesion under flow, unless platelets were added
together with the tumour cells. These findings strongly suggest
that thrombin might enhance tumour metastasis ofmalignant cells,
which do not respond to thrombin alone, by increasing the throm-
bogenicity of the endothelium that, in turn, increases tumour cell
adhesion via EC-bound platelets.
Finally, the present work sheds additional light on the involve-
ment of the haemostatic system in tumour metastasis and suggests
that anti-metastatic treatment based on blockade of the platelet
and/or EC thrombin receptor might offer a therapeutic benefit.
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